Detailed Information on Publication Record
2019
DNA methylation and hydroxymethylation patterns in acute myeloid leukemia patients with mutations in DNMT3A and IDH1/2 and their combinations
ŠESTÁKOVÁ, Šárka, Zdeněk KREJČÍK, Adam FOLTA, Eva CEROVSKÁ, Cyril ŠÁLEK et. al.Basic information
Original name
DNA methylation and hydroxymethylation patterns in acute myeloid leukemia patients with mutations in DNMT3A and IDH1/2 and their combinations
Authors
ŠESTÁKOVÁ, Šárka (203 Czech Republic), Zdeněk KREJČÍK (203 Czech Republic), Adam FOLTA (203 Czech Republic), Eva CEROVSKÁ (203 Czech Republic), Cyril ŠÁLEK (203 Czech Republic), Michaela MERKEROVÁ DOSTÁLOVÁ (203 Czech Republic), Pavla PECHERKOVÁ (203 Czech Republic), Zdeněk RÁČIL (203 Czech Republic, belonging to the institution), Jiří MAYER (203 Czech Republic, belonging to the institution), Petr CETKOVSKÝ (203 Czech Republic) and Hana REMEŠOVÁ (203 Czech Republic, guarantor)
Edition
Cancer Biomarkers, Amsterdam, IOS Press, 2019, 1574-0153
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30204 Oncology
Country of publisher
Netherlands
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 3.436
RIV identification code
RIV/00216224:14110/19:00108493
Organization unit
Faculty of Medicine
UT WoS
000469000100005
Keywords in English
AML; DNMT3A and IDH1/2 mutations; methylation; hydroxymethylation; GZMB; CHFR
Tags
International impact, Reviewed
Změněno: 11/5/2020 09:46, Mgr. Tereza Miškechová
Abstract
V originále
BACKGROUND: Aberrant epigenetic patterns are a hallmark of acute myeloid leukemia (AML). Mutations in profound epigenetic regulators DNMT3A and IDH1/2 often occur concurrently in AML. OBJECTIVES: The aim was to analyze DNA methylation, hydroxymethylation and mRNA expression profiles in AML with mutations in DNMT3A and IDH1/2 (individually and in combinations). METHODS: Infinium MethylationEPIC BeadChip (Illumina) covering 850,000 CpGs was utilized. The validation of hydroxy-/methylation data was done by pyrosequencing. HumanHT-12 v4 Expression BeadChip (Illumina) was used for expression examination. RESULTS: Hierarchical clustering analysis of DNA hydroxy-/methylation data revealed clusters corresponding to DNMT3A and IDH1/2 mutations and CD34+ healthy controls. Samples with concurrent presence of DNMT3A and IDH1/2 mutations displayed mixed DNA hydroxy-/methylation profile with preferential clustering to healthy controls. Numbers and levels of DNA hydroxymethylation were low. Uniformly hypermethylated loci in AML patients with IDH1/2 mutations were enriched for immune response and apoptosis related genes, among which hypermethylation of granzyme B (GZMB) was found to be associated with inferior overall survival of AML patients (P = 0.035). CONCLUSIONS: Distinct molecular background results in specific DNA hydroxy-/methylation profiles in AML. Site-specific DNA hydroxymethylation changes are much less frequent in AML pathogenesis compared to DNA methylation. Methylation levels of enhancer located upstream GZMB gene might contribute to AML prognostication models.
Links
NV15-25809A, research and development project |
|